The contract allows Avaxia Biologics to complete the pre-clinical pharmacology studies for oral antibody therapy.
Avaxia CEO Barbara Fox said they look forward to working with BARDA to develop a novel drug that can effectively protect the gastrointestinal tract from radiation damage.
"Besides providing the company with additional scientific infrastructure, the research to be conducted on this therapeutic will contribute to and support our innovative technology platform and bolster work being done in the related field of inflammatory bowel disease," Fox said